Weekly paclitaxel and trastuzumab as first-line chemotherapy in patients with her-2 positive metastatic breast cancer

被引：0
|
作者：
Kim, Jin-Soo [1 ]
Han, Hye-Suk [1 ]
Im, Seock-Ah [1 ]
Oh, Do-Youn [1 ]
Han, Won-Shik [1 ]
Lee, Se-Hoon [1 ]
Kim, Dong-Wan [1 ]
Kim, Tae-You [1 ]
Noh, Dong-Young [1 ]
Bang, Yung-Jue [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [1] Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Gasparini, Giampietro
    Gion, Massimo
    Mariani, Luigi
    Papaldo, Paola
    Crivellari, Diana
    Filippelli, Gianfranco
    Morabito, Alessandro
    Silingardi, Vittorio
    Torino, Francesco
    Spada, Antonella
    Zancan, Matelda
    De Sio, Livia
    Caputo, Antonio
    Cognetti, Francesco
    Lambiase, Antonio
    Amadori, Dino
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (03) : 355 - 365
  • [2] Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Giampietro Gasparini
    Massimo Gion
    Luigi Mariani
    Paola Papaldo
    Diana Crivellari
    Gianfranco Filippelli
    Alessandro Morabito
    Vittorio Silingardi
    Francesco Torino
    Antonella Spada
    Matelda Zancan
    Livia De Sio
    Antonio Caputo
    Francesco Cognetti
    Antonio Lambiase
    Dino Amadori
    Breast Cancer Research and Treatment, 2007, 101 : 355 - 365
  • [3] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [4] WEEKLY PACLITAXEL (PCT) plus TRASTUZUMAB (T) AS FIRST-LINE THERAPY OF PATIENTS (PTS) WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER (MBC): A MULTICENTER RANDOMIZED PHASE II TRIAL
    Gasparini, Giampietro
    Crivellari, Diana
    Filippelli, Gianfranco
    Morabito, Alessandro
    Silingardi, Vittorio
    De Sio, Livia
    Spada, Antonella
    Papaldo, Paola
    Carillio, Guido
    Veronesi, A.
    Zancan, Matelda
    Gion, Massimo
    Caputo, Antonio
    Cognetti, Francesco
    Amadori, Dino
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [5] Liposomal doxorubicin in combination with trastuzumab and docetaxel as first line chemotherapy in HER-2 metastatic breast cancer patients
    Bighin, C.
    Puglisi, F.
    Cavazzini, G.
    Olmeo, N.
    Colucci, G.
    Garrone, O.
    Paccagnella, A.
    Labianca, R.
    Crino, L.
    Simoncini, E.
    Manzione, L.
    Nardi, M.
    Cortesi, E.
    Venturini, M.
    ANNALS OF ONCOLOGY, 2005, 16 : 9 - 9
  • [6] Magnitude of HER2 amplification as a predictive factor for HER2-overexpressing metastatic breast cancer treated with weekly paclitaxel plus trastuzumab as first-line chemotherapy
    Han, H.
    Kim, J.
    Im, S.
    Park, J.
    Oh, S.
    Oh, D.
    Kim, J.
    Lee, K.
    Kim, T.
    Bang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Preliminary clinical results of a randomized phase IIb study of weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/neu positive metastatic breast cancer (MBC).
    Gasparini, G
    Morabito, A
    De Sio, L
    Carillio, G
    Gion, M
    Zancan, M
    Rocco, S
    Crivellari, D
    Spada, A
    Veronesi, A
    Filippelli, G
    Silingardi, V
    Cognetti, F
    Papaldo, P
    Amadori, D
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S51 - S51
  • [8] Weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/NEU positive metastatic breast cancer (MBC):: final results of a multicenter randomized phase IIb trial
    Gasparini, G
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [9] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Infante, Jeffrey R.
    Yardley, Denise A.
    Burris, Howard A., III
    Greco, F. Anthony
    Farley, Cindy P.
    Webb, Charles
    Spigel, David R.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
  • [10] Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer
    Wist, EA
    Sommer, HH
    Ostenstad, B
    Risberg, T
    Fjæstad, K
    ACTA ONCOLOGICA, 2004, 43 (01) : 11 - 14
12345